Review Article

Cardiovascular Disease in Rheumatoid Arthritis: A Systematic Literature Review in Latin America

Juan Camilo Sarmiento-Monroy, Jenny Amaya-Amaya, Juan Sebastián Espinosa-Serna, Catalina Herrera-Díaz, Juan-Manuel Anaya, and Adriana Rojas-Villarraga

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, 111221 Bogotá, Colombia

Correspondence should be addressed to Adriana Rojas-Villarraga, samanda.rojas@urosario.edu.co

Received 31 July 2012; Accepted 27 August 2012

Copyright © 2012 Juan Camilo Sarmiento-Monroy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Cardiovascular disease (CVD) is the major predictor of poor prognosis in rheumatoid arthritis (RA) patients. There is an increasing interest to identify “nontraditional” risk factors for this condition. Latin Americans (LA) are considered as a minority subpopulation and ethnically different due to admixture characteristics. To date, there are no systematic reviews of the literature published in LA and the Caribbean about CVD in RA patients. Methods. The systematic literature review was done by two blinded reviewers who independently assessed studies for eligibility. The search was completed through PubMed, LILACS, SciELO, and Virtual Health Library scientific databases. Results. The search retrieved 10,083 potential studies. A total of 16 articles concerning cardiovascular risk factors and measurement of any cardiovascular outcome in LA were included. The prevalence of CVD in LA patients with RA was 35.3%. Non-traditional risk factors associated to CVD in this population were HLA-DRB1 shared epitope alleles, rheumatoid factor, markers of chronic inflammation, long duration of RA, steroids, familial autoimmunity, and thrombogenic factors. Conclusions. There is limited data about CVD and RA in LA. We propose to evaluate cardiovascular risk factors comprehensively in the Latin RA patient and to generate specific public health policies in order to diminish morbi-mortality rates.

1. Introduction

RA is the most common inflammatory arthropathy worldwide with a prevalence of 0.5–1.0% in industrialized countries [1]. The annual incidence is highly variable (12 to 1,200 per 100,000 population) and is dependent on a variety of factors, including sex, ethnicity, and age [2]. RA is a chronic, multiorgan, and complex disease with an autoimmune basis. The disease is three times more frequent in women than men [1]. RA can damage virtually any extraarticular tissue due to a systemic proinflammatory state. Cardiovascular disease (CVD) is considered an extraarticular manifestation (EAM) [3] and a major predictor of poor prognosis [2]. Several studies have documented a high prevalence of CVD in many autoimmune diseases (ADs) [2, 4–14]. Several traditional risk factors such as obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), metabolic syndrome (MetS), hypertension, physical inactivity, advanced age, male gender, family history of CVD, hyperhomocysteinemia, and tobacco have been associated with CVD in RA patients [15–20]. In fact, seropositive RA may, like diabetes, act as an independent risk factor for CVD [21]. A proinflammatory state [7], insulin resistance [22], hyperhomocysteinemia [23], and oxidative stress [24] are common characteristics of both RA and atherogenesis. Nevertheless, excessive cardiovascular events observed in RA individuals are not fully explained by these traditional risk factors [7, 24]. Hence, there is an increasing interest in identifying “nontraditional” [4, 5] novel risk factors (i.e., genetic polymorphisms, autoantibodies, medication, duration of RA, high disease activity, development of EAM and many others) in order to explain the development
of early endothelial dysfunction, increased intima-medial thickness (IMT), and finally, accelerated atherosclerosis [25]. The finding and understanding of these predisposing factors will allow us to better describe cardiovascular subphenotypes including hypertension, stroke, coronary artery disease (CAD), angina, myocardial infarction (MI), arrhythmias, ventricular diastolic dysfunction [26, 27], congestive heart failure (CHF), thrombosis, and peripheral arterial disease [16, 28].

Life expectancy of patients with RA is three to ten years less than that of the general population [29]. Although it is well established that cardiovascular mortality is higher in RA, the reasons for this remain elusive [30]. Currently, ischemic heart disease (IHD) secondary to atherosclerosis is the most prevalent cause of death associated with CVD in patients with RA [31]. CVD accounts for 30–50% of all deaths in RA patients [3]. Thus, RA added to CVD as the leading cause of death around the world [32, 33] requires us to take these diseases more seriously. Therefore, doctors need to be more committed to assessing, monitoring, and treating cardiovascular risk factors in the early stages as well as to promoting lifestyle changes in order to diminish morbidity and mortality rates in RA individuals.

Hispanics are considered a minority group due to a mixed ethnicity (so called mestizos) that is mainly derived from a European and Amérindian inheritance [34]. Therefore, they represent a unique population. So far, some studies of RA have documented differences in health status, disease prevalence, treatment outcomes, and healthcare use among different ethnic groups [35, 36] which suggest that minority health disparities influence RA. Moreover, CVD is still one of the most important comorbidities in this subpopulation due to augmented mortality secondary to accelerated atherosclerosis, systemic inflammation, and MI or stroke [37–39].

RA is not uncommon in LA, the geographical area defined by Mexico, Central America, South America, and the islands of the Caribbean [1]. Overall, RA affects 0.5% of LA [40]. In Argentina, Spindler et al. [41] reported an overall prevalence ratio (per 1,000) of 1.97 (95% CI: 1.8–2) for both sexes, 0.6 (95% CI: 0.49–0.73) for men and 3.2 (95% CI: 2.9–3.5) for women. Peláez-Ballestas et al. [42] found a prevalence of 0.7–2.8% in Mexican patients. In an isolated African Colombian population, a prevalence of 0.01% was reported [43]. However, CVD has not been systematically assessed in LA and only a few studies have evaluated some of the traditional and nontraditional risk factors, cardiovascular subphenotypes, and mechanisms underlying the accelerated atherosclerosis that is characteristic of this population. Therefore, in this study, a systematic review of CVD in LA patients with RA was done.

2. Material and Methods

2.1. Search Strategy. A systematic literature review of articles on CVD and RA in LA was carried out in the following databases: PubMed, LILACS, SciELO, and Virtual Health Library (VHL). It included articles published between January 1947 and May 2012. Two reviewers did the search independently (SMJC and HDAC) while applying the same selection criteria described below. The search results were compared and disagreements were resolved by consensus. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in data extraction, analysis, and reporting [44].

The search was done in PubMed, using the following Medical Subject Headings (MeSH) terms: “Arthritis, Rheumatoid,” “Latin America,” “Ethnic Groups,” “Minority Groups,” “Latin America/Epidemiology,” “Latin America/ Ethnology,” “Brazil,” “Mexico,” “Colombia,” “Chile,” “Cuba,” “Panama,” “Venezuela,” “Bolivia,” “Peru,” “Argentina,” “Uruguay,” “Paraguay,” “Ecuador,” “Nicaragua,” “Surinam,” “French Guyana,” “Guatemala,” “Honduras,” “Belize,” “Costa Rica,” “El Salvador,” “Puerto Rico,” “Dominican Republic,” and “Haiti.” Each one of them was cross-referenced with the following MeSH terms: “Cardiovascular Diseases,” “Hypertension,” “Thrombosis,” “Stroke,” “Myocardial Infarction,” and “Coronary Artery Disease.” Each term was cross-referenced for the greatest number of results. No limits regarding language, period of publication, or publication type were used. In a quality control assessment of the first systematic search, it was evident that some publications were missed when only MeSH terms were used. Therefore, a second search was done by implementing key words. In the second search, also without limits, MeSH terms (“Hispanic Americans” and some of the previously described terms such as “Arthritis, Rheumatoid,” “Latin America” and “Minority Groups”) and key words (Rheumatoid Arthritis was matched with every country and Hispanics with RA) were included.

A similar strategy was followed for the other databases. Each MeSH term was translated into DeCS (Health Sciences Descriptors) in order to explore sources of information in Portuguese, Spanish, and English through SciELO, LILACS and VHL databases. The following terms were selected: “Artritis Reumatoide,” “América Latina,” “Salud de Minorías,” “Grupos Étnicos,” “Brasil,” and “Haití” (24 countries, as well as PubMed). Then each of the terms was cross-referenced with the following: “Enfermedades Cardiovasculares,” “Hipertension,” “Embolia y Trombosis,” “Accidente Cerebrovascular,” “Infarto del Miocardio,” and “Enfermedad Coronaria” for the first search. Each term was cross-referenced for the greatest number of results. Once again, no limits were used. For the second search in SciELO, some of the DeCS terms and keywords included were Artritis Reumatoide, América Latina, Salud de Minorías, Grupos Étnicos, “Enfermedades Cardiovasculares,” “Hipertension,” “Embolia y Trombosis,” “Accidente Cerebrovascular,” “Infarto del Miocardio,” and “Enfermedad Coronaria.” Both Spanish (Artritis Reumatoide) and English (Rheumatoid Arthritis) key words were matched with every country (Brazil to Haiti). “Artrite Reumatoide” was included as an additional term for Brazil in the search for articles published about CVD in this country. Likewise, in two remaining databases—LILACS and VHL (all sources)—both Spanish (Artritis Reumatoide) and English (Rheumatoid Arthritis) key words were matched with every country (Brazil to Haiti). As in SciELO, “Artrite Reumatoide” was included as an additional term for Brazil.
2.2. Study Selection, Data Extraction, and Quality Assessment. A study was included if (a) the abstract was available, (b) it contained original data, and (c) it used accepted classification criteria for RA and measured cardiovascular risk factors (traditional, nontraditional) and/or any of the cardiovascular subphenotypes. Articles were excluded from the analysis if they dealt with juvenile idiopathic arthritis or were done on animal models (i.e., murine models) instead of RA patients. Studies were also excluded if they were reviews or case reports, if they discussed topics not related to CVD, and/or were not done on an LA population. Those references from the articles that seemed to be relevant for the present paper were hand-searched and were included in the discussion. Abstracts and full text articles were reviewed to find eligible studies. Duplicate papers were excluded.

Three blinded reviewers (SMJC, AAJC, and HDAC) organized selected articles on the basis of publication source, author, cardiovascular outcome, and traditional and nontraditional cardiovascular risk factors as well as subphenotypes evaluated. Moreover, a descriptive analysis from these data was completed. Articles were not included in the analysis when there was a lack of inclusion criteria, insufficient data, and statistical significance. A database with pertinent information from these studies which included authors, name of study, country, language, study design, number of patients, objective, cardiovascular outcome, method of hypothesis testing, results, limits/bias of the study, and reference was created. Disagreements between the reviewers were resolved by consensus. Each record was classified based on the quality score of the studies that was assigned by applying the levels established by the Oxford Centre for Evidence-based Medicine 2011 in order to evaluate the risk of bias [45].

3. Results

3.1. Systematic Literature Review. There were 3,897 articles identified in the first and 1,285 articles in the second search in PubMed (total of 5,182). Additional records identified through other sources included 206 articles from SciELO in the first search and 273 in the second one, 34 and 465 from LILAC, and 2,496 and 1,427 from VHL. Therefore, the database searches provided a total of 10,083 publications. Of these, 9,998 studies were discarded because they did not meet the eligibility criteria. After this exclusion, 83 articles were assessed and duplicates were identified (64 papers). A total of 21 full text articles were assessed for eligibility. Finally, only 16 articles [25, 30, 46–59] that had interpretable data and fulfilled the eligibility criteria were included. Of the selected articles, there were 5 from Mexico, 3 from Brazil and Colombia, 2 from Argentina, and 1 from Chile, Cuba and Puerto Rico, respectively. Seven were cross-sectional, 6 were case controls, 2 descriptive/retrospective, and only one corresponded to a cohort study. Half the studies had a sample size that was less than 100 patients. The flow chart for systematic literature review and articles included in the analysis are shown in Figure 1.

3.2. Risk Factors, Physiopathological Changes, and Subphenotypes of CVD. The prevalence of CVD in LA patients with RA was 35%. Several traditional cardiovascular risk factors such as dyslipidemia [25, 30, 48, 50, 51, 53, 55, 56, 58, 59], hyperhomocysteinemia [30, 48], smoking [25, 30, 48, 50], T2DM [25, 48, 50, 53, 56, 58], MetS [25, 50, 53], hypertension [30, 48–50, 52–56, 58], male gender [25, 46, 49, 49, 52–55], obesity [25, 49, 50, 52], physical inactivity [25, 50], and family history of CVD [25, 55] were reported. Several studies were associated with nontraditional risk factors, previously described in the literature, such as HLA-DRB1 shared epitope (SE) allele [25], rheumatoid factor (RF) [25, 30, 46, 49, 52, 55, 57, 58], anticyclic citrullinated peptide antibody (anti-CCP) [25, 55], and other autoantibodies [51]. These included anticyclediopilins (aCL), anti-β2 glycoprotein I (anti-β2GPI), antioxidized low-density lipoprotein (anti-oxLDL), and anticoagulant proteins 60/65 antibodies (anti-HSP 60/65) [52]. Other nontraditional factors include long duration of RA (>10 years) [25, 55], markers of chronic inflammation such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) [48, 49, 52, 55], high disease activity score-28 (DAS-28) [25, 49, 52, 57] and simplified disease activity index (SDAI) [52], presence of EAM [25, 46, 55, 57], medications like methotrexate (MTX) [25, 30, 49], and steroids [25, 30, 55–57, 59]. The last factors described were thrombogenic factors such as von Willebrand factor (vWF) [49] and fibrinogen [52], and novel risk factors like poliautoimmunity (defined as the presence of more than one autoimmune disease in a single patient) [25, 46, 55, 58], and familial autoimmunity [25] (diverse autoimmune diseases cooccurring within families). These factors and their respective prevalence or associations are depicted in Table 1. Many groups described endothelial dysfunction, an increased IMT, and atherosclerosis plaque in RA patients [25, 49, 51, 52]. A broad spectrum of cardiovascular subphenotypes including stroke, CAD, MI, hypertension, thrombosis, peripheral arterial disease, and ventricular diastolic dysfunction were described in LA individuals with RA. Hypertension was the most common outcome in almost all studies with an overall prevalence of 28% (range 11.2–80.6%) [25, 48, 50, 53–56, 58, 59]. The average prevalence of CAD and stroke was 9% [47, 54, 58] and 2.5% [30, 46, 48, 58, 59], respectively. Figure 2 shows the prevalences of CVD in LA and the Caribbean.

4. Discussion

To date, the literature evaluating CVD outcomes in LA individuals with RA is scarce. Only a few studies have assessed the classic and nontraditional risk factors in this subpopulation.

4.1. Cardiovascular Disease as the Leading Cause of Mortality in LA. CVD is the leading cause of mortality worldwide. On the American continent, the prevalence and incidence of CVD is growing at an alarming rate. The World Health Organization (WHO) forecasts that the number of deaths in the region attributed to CVD will increase by more than
60% between 2000 and 2020 unless preventive measures are taken [60]. Thus, this chronic disease is one of the major causes of death around the world [33]. Thanks to the CARMELA initiative study, many traditional factors have been described in LA population such as hypertension, dyslipidemia, obesity, smoking, T2DM, and MetS [61].

Table 2, which was adapted from the Pan American Health Organization report [62], shows the mortality rates of CVD in the Americas as of 2007–2009 in terms of IHD and cerebrovascular disease. The data on this table is organized by country and region thus making it possible to contrast mortality rates from these two diseases in the United States of America (USA) and Canada with LA and the Caribbean. Generally, high rates of death were mostly observed in developed countries such as USA and Canada with 136.3/100,000 people. Incidence of mortality in LA and the Caribbean due to IHD and cerebrovascular disease is 55.8/100,000 and 44.8/100,000 people, respectively. Individuals living in developed countries have more risk factors, for example, inappropriate life styles, that contribute to a higher rate of death from CVD. Thus, it is important to promote healthy habits among the general population and in patients with an early diagnosis of RA in order to prevent CVD. In specific LA countries, numbers show high rates of IHD in countries such as Cuba (140.1/100,000 people) and Puerto Rico (100.7/100,000 population). The importance of the numbers lies in the fact that they can be analyzed from the perspective of increased risk of CVD in RA in comparison to the general population. Therefore, it is important to discriminate mortality CVD rates by patients with chronic inflammatory diseases (i.e., RA).

LA has a growing population and it is a very dynamic region with an estimated population of 515 million. As mentioned before, the RA prevalence reported in LA is considered to be less than 0.5% [63, 64]. The heterogeneity across LA is expected due to the high degree of admixture between subpopulations. Hispanic/Latino populations are the result of a two-way admixture between Amerindian
### Table 1: Traditional, nontraditional risk factors, physiopathological changes, and subphenotypes of cardiovascular disease and rheumatoid arthritis in Latin America.

| Ref. | Country | Author | Prevalence of CVD in RA (%) | N | Traditional risk factors of CVD n/N (%) | Nontraditional risk factors of CVD n/N (%) | Physiopathological changes in CVD n/N (%) | Subphenotype of CVD described n/N (%) |
|------|---------|--------|----------------------------|---|----------------------------------------|---------------------------------------------|------------------------------------------|--------------------------------------|
| [46] |        | Orozco-Alcalá et al. | 44.7 | 38 | Male gender 12/38 (31.6) | Polyautoimmunity 6/38 (15.8); RF 32/38 (84.2); EAM 16/38 (42.1); GC 9/38 (23.7); RA duration over 10 years 17/38 (44.7) | N/A | Stroke 10/38 (26.3), MI 3/38 (7.9), CHF 3/38 (7.9), acute pulmonary embolism 1/38 (2.6) |
| [47] |        | Espinola-Zavaleta et al. | 14.3 | 37 (14 with RA) | Dyslipidemia: TGL 106.2 ± 55.1; male gender 2/14 (14.3) | RA duration 8.2 ± 7.1 | N/A | Alterations in myocardial perfusion: Subclinical CAD 2/14 (14.3) |
| [48] | Mexico | Lopez-Olivo et al. | 13.8 | 152 RA patients/153 controls | Obesity: BMI 25 (16–36); dyslipidemia: hypercholesterolemia 5/152 (3.3), T2DM 8/152 (5.3); male gender 26/152 (17.1); hyperhomocysteinemia 31/152 (20.4) and smoking 56/152 (36.8) | RF 149 (0–3,050); CRP (mg/dL) 17 (3–126); RADAR 1.0 (0.1–2.7); HAQ-DI 0.7 (0.2–7.1); MTX 14/31 (45.2) | N/A | Hypertension 17/152 (11.2), stroke 4/152 (2.6) |
| [49] |        | Daza, et al. | 7.3 | 55 RA patients/22 controls | Obesity: BMI 27.5 ± 4.05/24.48 ± 3.73 | RF 506.5 (347.1–665.8) / 13.3 (5.8–20.8); CRP (mg/dL) 1.48 (1.05–1.9) / 0.6 (0.02–1.2); ESR 28.47 ± 14.48/9.65 ± 3.56; DAS 28 4.77 (4.5–5.1) /MTX 45/55 (81.8), SSZ 6/55 (10.9), GC 8/55 (14.5); vWF 145.6 ± 30.1 / 121.8 ± 37.2 | N/A | Hypertension 47/192 (24.5) |
| [50] |        | Zonana-Nacach et al. | 24.5 | 192 (107 RA and 85 SLE patients) | Obesity 49/192 (25.5), dyslipidemia 49/192 (25.5), T2DM 14/192 (7.3), MetS 18.7, physical inactivity 75/192 (87), and smoking 28/192 (14.6) | RA duration 135 ± 112 (months); Housewife 102/192 (53) | N/A | Hypertension 47/192 (24.5) |
| Ref. | Country | Author | Prevalence of CVD in RA (%) | N | Cardiovascular outcome measured | Traditional risk factors of CVD n/N (%) | Nontraditional risk factors of CVD n/N (%) | Physiopathological changes in CVD described n/N (%) | Subphenotype of CVD described n/N (%) |
|------|---------|--------|-----------------------------|---|---------------------------------|--------------------------------------|---------------------------------------------|-------------------------------------------|----------------------------------|
| [52] | Brazil  | Pereira et al. | 14.1g | 71 RA patients/51 controls | Male gender | 7/71 (9.9) | CRP*: 8.64 ± 8.27/19.75 ± 25.08, ESR*: 24.1 ± 14.6/34.07 ± 23.54, DAS 28: 4.24 ± 1.02/4.64 ± 1.05, SDAP*: 35.54 ± 12.34/48.5 ± 30.28; MTP (mg/w): 20 ± 5/19.09 ± 5.74, GC (mg/day): 7.25 ± 2.75/7.72 ± 3.59; fibrinogen*: 326.04 ± 113.56/371.94 ± 121.08 | IMT*: 0.72 ± 0.17/0.67 ± 0.15 (mm). Carotid plaques (IMT > 1.5 mm) 10/71 (14.1)/1 (1.9) | N/A |
| [51] | Brazil  | Pereira et al. | 14.1g | 71 RA patients/53 controls | Dyslipidemia*: CT 243.3 ± 31.2/191.54 ± 36.21, male gender | Obesity: BMI 26.6 ± 5.1/26.8 ± 4.3, dyslipidemia: HDL 58.9 ± 16.4/52.7 ± 12.1, LDL 109.9 ± 33.2/122.8 ± 37.7, T2DM 32/283 (11.3)/6/226 (2.7), MetS 111/283 (39.2)/4/226 (19.5), male gender 50 (17.7)/34 (15) | | | |
| [53] | de Cunha et al. | Brazil  | 80.6g | 283 RA patients/226 controls | N/A | N/A | Hypertension*: 228 (80.6)/95 (42) | | |
| Ref. | Country | Author | N | Prevalence of CVD in RA (%) | Traditional risk factors of CVD n/N (%) | Nontraditional risk factors of CVD n/N (%) | Physiopathological changes in CVD n/N (%) | Subphenotype of CVD described n/N (%) |
|------|---------|--------|---|-----------------------------|-----------------------------------------|------------------------------------------|------------------------------------------|--------------------------------------|
| [54] | Colombia | Pineda et al. | 41 | Male gender 12/41 (29) | Obesity 23/140 (16), dyslipidemia 49/140 (35), T2DM 6/140 (4), MetS 61/140 (44), physical inactivity 119/140 (85), male gender 16/23 (72), family history of CHD 22/140 (16), ever smoking 61/140 (44), and history of hormone replacement therapy 10/140 (7) | N/A | N/A | Hypertension (24.2), CAD 9/41 (8.2) |
| [25] | Colombia | Rojas-Villarraga et al. | 140 | Dyslipidemia 64/534 (10), male gender 80/538 (15) | Poly-autoimmunity 48/538 (9); RF 246/385 (64), anti-CCP antibodies 146/183 (80); CRP 8.65 ± 20.21, ESR 38.86 ± 25.93; EAM 113/538 (21); GC 39/486 (8); RA duration 12.53 ± 8.08§ | N/A | N/A | Hypertension 57/140 (41) |
| [55] | Ortega-Hernandez et al. | 538 | Dyslipidemia 89/137 (65), T2DM 2/137 (1.45), and male gender N/A 11/137 (8) | GC 71/137 (51.8) | N/A | N/A | Hypertension 128/534 (24), thrombosis 43/534 (8) |
| [56] | Argentina | Larroudé et al. | 137 | Obesity; BMI 26 (18–39), dyslipidemia 18/54 (33), family history of CVD 7/54 (13), hyperhomocysteinemia 38/54 (70), and smoking 21/54 (39) | RF 50/54 (92), aCL† IgM 3 (0.53–23)/1.6 (0.21–10.6) IgG 4.3 (0.3–85; 2.5/0.123); CRP 0.73 (0.04–5.96)/0.31 (0.05–2.88), ESR 27 (3–99); MTX 41/54 (75), GC 42/54 (77); RA duration 9.5 (0.2–32)§ | N/A | N/A | Hypertension 21/54 (39), stroke 2/54 (3.7), stable angina 2/54 (3.7) |
| [57] | Argentina | Lascano et al. | 32 RA patients/32 controls | N/A | N/A | N/A | Ventricular diastolic dysfunction 15/32 (47) |
| [30] | Chile | Cisternas et al. | 46.4 | Obesity; BMI 26 (18–39), dyslipidemia 18/54 (33), family history of CVD 7/54 (13), hyperhomocysteinemia 38/54 (70), and smoking 21/54 (39) | RF 50/54 (92), aCL† IgM 3 (0.53–23)/1.6 (0.21–10.6) IgG 4.3 (0.3–85; 2.5/0.123); CRP 0.73 (0.04–5.96)/0.31 (0.05–2.88), ESR 27 (3–99); MTX 41/54 (75), GC 42/54 (77); RA duration 9.5 (0.2–32)§ | N/A | N/A | Hypertension 21/54 (39), stroke 2/54 (3.7), stable angina 2/54 (3.7) |
| Ref. | Country   | Author               | N  | Prevalence of CVD in RA (%) | Cardiovascular outcome measured                                                                 |
|------|-----------|----------------------|----|-----------------------------|---------------------------------------------------------------------------------------------------|
| [58] | Cuba      | Acosta et al.⁰       | 34.1| 172                         | **Cardiovascular outcome measured**                                                              |
|      |           |                      |    |                             | Traditional risk factors of CVD n/N (%)                                                         |
|      |           |                      |    |                             | Dyslipidemia 10/172 (5.8), T2DM 16/172 (9.3), and male gender 29/172 (16.9)                      |
|      |           |                      |    |                             | Nontraditional risk factors of CVD n/N (%)                                                      |
|      |           |                      |    |                             | Polyautoimmunity 2/172 (1.1); RF 52/85 (61.1)                                                   |
|      |           |                      |    |                             | Physiopathological changes in CVD n/N (%)                                                       |
|      |           |                      |    |                             | Hypertension 46/172 (26.7), stroke 1/172 (0.5), CAD 8/172 (4.6), and peripheral vascular disease 4/172 (2.3) |
| [59] | Puerto Rico| Santiago-Casas et al. ² | 55.9| 214                         | **Subphenotype of CVD described n/N (%)**                                                       |
|      |           |                      |    |                             | **Cardiovascular outcome measured**                                                              |
|      |           |                      |    |                             | Traditional risk factors of CVD n/N (%)                                                         |
|      |           |                      |    |                             | Dyslipidemia ² (9.1)-(52.7)-(58.4) T2DM ² (9.1)-(52.7)-(58.4) MetS (18.2)-(39.6)-(43.4) Smoking (4.5)-(11.0)-(7.9) |
|      |           |                      |    |                             | Nontraditional risk factors of CVD n/N (%)                                                      |
|      |           |                      |    |                             | RF (52.4)-(52.9)-(57.1); ESR (81.0)-(92.2)-(91); Steroids ² (54.5)-(78.0)-(82.2); RA duration ³ (3.4 ± 2.9)-(9.5 ± 8.2)-(13.6 ± 10.7) |
|      |           |                      |    |                             | Physiopathological changes in CVD n/N (%)                                                       |
|      |           |                      |    |                             | Hypertension ² (13.6)-(40.7)-(76.2), MI (0)-(2.2)-(9.1), angina pectoris (0)-(1.1)-(4.0), stroke (0)-(1.1)-(8.0), peripheral artery disease (0)-(1.1)-(5.0), and CHF (0)-(1.1)-(5.0) |

CVD: cardiovascular disease; RA: rheumatoid arthritis; RF: rheumatoid factor; EAM: extraarticular manifestations; GC: glucocorticoids; N/A: not available; MI: myocardial infarction; CHF: congestive heart failure; TGL: triglycerides; CAD: coronary artery disease; BMI: body mass index; T2DM: type 2 diabetes mellitus; CRP: C-reactive protein; RADAR: rapid assessment of disease activity in rheumatology; HAQ-DI: health assessment questionnaire disability index; MTX: methotrexate; ESR: Erythrocyte Sedimentation Rate; DAS-28: Disease Activity Score-28; SSZ: sulfasalazine; vWF: von Willebrand Factor; IMT: intima-media thickness; MetS: metabolic syndrome; SDAE: simplified disease activity index; TC: total cholesterol; anti-CCP: anti-cyclic citrullinated peptide antibodies; aCL: anticardiolipins antibodies; anti-B2GPI: anti-β-2 glycoprotein I antibodies; anti-HSP 60/65: anti-heat shock proteins 60/65 antibodies; anti-LPL: antilipoprotein lipase antibodies; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.

⁰Only descriptive study, which evaluated causes of mortality in adult patients with RA.

¹By echocardiogram and gammagrapy.

²Data from patients with RA 14/37 (37.8).

³Data from patients with hyperhomocysteinemia (>15 μmol/L).

⁴Exclusion criteria: patient with traditional cardiovascular risk factors.

⁵Only female were included, each with at least 5 years of duration of the disease and between 35 and 54 years of age.

⁶Not CVD subphenotype measured. Prevalence regarding presence of atherosclerosis plaque.

⁷Only female were included.

⁸Exclusion criteria: smoking, diabetes and hypertension pregnancy, renal failure, chronic hepatopathy, nephritic syndrome, hypothyroidism and use of statins/fibrates.

⁹RA patients versus controls.

¹⁰Exclusion criteria: smoking, diabetes, and hypertension.

¹¹High blood pressure was defined above 130/85 mmHg.

¹²The objective was to analyze causes and direct costs of hospitalization of Colombian patients with RA.

¹³Sample population was originally from Northwestern Colombia. They are considered ethnically different.

¹⁴Exclusion criteria: any symptoms of heart disease or risk factors for CVD.

¹⁵Subjects over 60 years were excluded.

¹⁶Only cohort, 6 years followup. Low mortality rate 9/32 (5.2%).

¹⁷Three age group (<40 y)-(<40-59 y)-(>60 y). Elder people (>60 y) have more probability to develop CVD independent of RA.

¹⁸Mean ± standard deviation.

¹⁹Median (interquartile range).

²⁰Prevalence of CVD regarding the only subphenotype described.

²¹P values < 0.05 were considered significant.
and European populations or of three-way admixture of Amerindian, European, and West African populations [65]. Some studies have documented differences in the health status of, disease prevalence in, treatment outcome in, and healthcare use by different ethnic groups. Yazici et al. [35] compared patients from different ethnic groups with early RA using disease activity measures, identifying possible differences in patterns of clinical severity. They found that Hispanic patients with RA scored the worst in all self-report measures compared to Caucasians and African Americans with statistically significant differences in the Modified Health Assessment Questionnaire (MHAQ) functional score, psychological distress, and morning stiffness [35]. In a study of RA patients, Bruce et al. [36] demonstrated disparities between Caucasians and African Americans and Hispanics in disability, pain, and global health. Pain was worse in the latter two groups and global health was worse in Hispanics. The results of this exploratory study suggest that in a relatively similar cohort of patients with RA, minority health disparities exist [36]. Moreover, the prevalence of MI is high in Hispanics living in the USA, and coronary events are presented by people younger than in other minorities [48].
Table 2: Cardiovascular disease mortality in the Americas*.  

| Region                               | Annual deaths average (thousands)a | Mortality rate from IHDb,c | Mortality rate from cerebrovascular diseasea | Total |
|--------------------------------------|-----------------------------------|---------------------------|--------------------------------------------|--------|
| Americas                             | 6,447.2                           | 87.4                      | 45.1                                       |        |
| North America                        | 2,885                             | 136                       | 45                                         |        |
| Canada                               | 262.8                             | 109                       | 41.4                                       |        |
| United States of America             | 2,621.7                           | 139                       | 45.4                                       |        |
| Latin America and the Caribbean      | 3,562.2                           | 55.8                      | 44.8                                       |        |
| Latin America                        | 3,510.8                           | 56                        | 44.9                                       |        |
| Mexico                               | 549.4                             | 54.1                      | 27.5                                       |        |
| Central American Isthmus             | 226.1                             | 41.9                      | 24.4                                       |        |
| Belize                               | 1.2                               | 30.9                      | 25.7                                       |        |
| Costa Rica                           | 20.4                              | 48.4                      | 21.3                                       |        |
| El Salvador                          | 41                                | 56                        | 22.4                                       |        |
| Guatemala                            | 80.5                              | 25.5                      | 16.4                                       |        |
| Honduras                             | 37.5                              | N/A                       | N/A                                        |        |
| Nicaragua                            | 27.5                              | 54.2                      | 32.8                                       |        |
| Panama                               | 18.1                              | 57.2                      | 51.5                                       |        |
| Latin Caribbean                      | 270.5                             | N/A                       | N/A                                        |        |
| Cuba                                 | 83.9                              | 140                       | 80.6                                       |        |
| Dominican Republic                   | 60.1                              | N/A                       | N/A                                        |        |
| French Guiana                        | 0.9                               | N/A                       | N/A                                        |        |
| Haiti                                | 90                                | N/A                       | N/A                                        |        |
| Puerto Rico                          | 29.1                              | 101                       | 40.1                                       |        |
| Andean Area                          | 722.5                             | 58.7                      | 35.7                                       |        |
| Bolivia                              | 72.9                              | N/A                       | N/A                                        |        |
| Colombia                             | 260.6                             | 74.1                      | 38.7                                       |        |
| Ecuador                              | 74.5                              | 25.6                      | 34.1                                       |        |
| Peru                                 | 161.4                             | 27.8                      | 26.6                                       |        |
| Venezuela                            | 153.1                             | 81.4                      | 41                                         |        |
| Brazil                               | 1,261.1                           | 60.4                      | 62.2                                       |        |
| Southern Cone                        | 481.3                             | 49.1                      | 51.2                                       |        |
| Argentina                            | 315.6                             | 46.8                      | 48.2                                       |        |
| Chile                                | 98.2                              | 47.1                      | 46.8                                       |        |
| Paraguay                             | 36.1                              | 50.3                      | 55.5                                       |        |
| Uruguay                              | 31.3                              | 85.4                      | 103                                        |        |
| Non-Latin Caribbean                  | 51.3                              | 63.4                      | 63.8                                       |        |
| Guyana                               | 4.4                               | 80.9                      | 70.3                                       |        |
| Suriname                             | 3.8                               | 47                        | 72                                         |        |

* Adapted from [62]. The values were obtained from “Corrected Mortality” data. These values were computed by applying a correction algorithm for mortality underregistration and a redistribution algorithm for deaths from ill-defined causes. The methodology used is presented in Health Statistics from the Americas. 2006 edition (http://www.paho.org/HSA2006).

a Values are expressed in incidence rates/100,000 population (2007–2009).
b IHD: ischemic heart disease.
N/A: not available.

Nevertheless, only two studies in LA assessed mortality in RA patients. Orozco-Alcalá et al. [46] showed that there were no differences between RA patients and the general population concerning causes of death. Acosta et al. [58] demonstrated a mortality rate of 5.2% in a six-year followup. For both, the most frequent cause of death was CVD in 44.7% and 22.2% of the cases, respectively. In the other selected articles, a wide range of prevalence for CVD was
reported (13.8–80.6%). The highest prevalence was indicated by Santiago-Casas et al. [59] in Puerto Rican patients (55.9%) when the demographic characteristics, clinical manifestations, comorbidities, pharmacological profile, and functional status of different age groups were determined. Nevertheless, the fact that elderly people (>60 years) have a higher probability of developing CVD whether or not they have RA had to be taken into account for calculating a higher probability of developing CVD whether or not functional status of different LA countries were included and evaluated for cardiovascular outcomes in studies ranging from 1993 to 2012 (see Supplementary Table 1 in Supplementary Material available online at doi:1155/2012/371909). Common limiting factors in the sixteen studies analyzed included a lack of prospective follow up of RA patients and a general limitation on sample sizes. Most of the studies were either cross-sectional or case-control which in terms of evidence place them at level 4 [45]. Moreover, 50% of the studies included in the analysis had sample sizes of more than 100 RA patients. The rest of them had limited numbers of patients included, which was another common limit or direction limitation. The majority of the studies should be noted. This was the case for four of the studies, which were descriptive or did not calculate P values, adjusted odds ratio or confidence intervals.

There is insufficient literature regarding CVD in LA patients with RA. Although the number of patients assessed is not negligible, when the geographical area of LA, the diversity, and the admixture of the population are considered, there is a need to include true cohorts to ensure more decisive conclusions.

4.2. Traditional Risk Factors, CVD, and RA. RA is a relatively frequent AD, which is chronic in nature, and these patients are doubly at risk of developing any CVD subphenotype with respect to the non-RA population [66, 67]. In fact, IHD secondary to atherosclerosis is the most prevalent cause of death associated with CVD in patients with RA [30]. The worldwide prevalence of hypertension in RA is between 49 and 77% [5]. It is considered the most common comorbidity in Hispanic patients with RA. The most frequent classic risk factor for CVD in this systematic literature review (with more than 2,000 RA patients included) was hypertension as well. Nevertheless, a lower prevalence (27.9%) than that reported previously in other countries was found. Many of these predisposing factors have been described in LA studies: hypertension [30, 36, 53–55, 58, 59, 61, 68, 69], T2DM [25, 48, 50, 53, 56, 58], dyslipidemia [25, 58, 59, 70], MetS [17, 25, 50, 53, 68, 69, 71], and hyperhomocysteinemia [22, 25, 48, 72]. For details, see Table 3.

4.3. Nontraditional Risk Factors, CVD, and RA. Since there is no classification system for nontraditional risk factors, we would like to propose one. Our recommendation is to divide them into genetic, AD associated, and others. The genetic group includes both HLA and non-HLA genes. HLA-DRB1 SE alleles are related to chronic inflammation, endothelial dysfunction, premature death, and CVD itself [25, 73–80]. The non-HLA genes include polymorphisms in the endothelin-1 and methylene tetrahydrofolate reductase genes. Endothelin-1 enhances CVD by endothelial dysfunction and hypertension [81]. Methylene tetrahydrofolate reductase has been related to atherosclerosis and the clinical response to some Disease-Modifying Antirheumatic Drugs (DMARDs) [82]. Others genes are TNFA rs1800629 and NFKB1-94ATTG ins/del polymorphisms. These are associated with predisposition to cardiovascular complications in patients with RA, as subclinical and accelerated atherosclerosis [83, 84]. However, other gene polymorphisms placed outside the HLA region and not strongly associated with susceptibility to RA and CVD. Rodriguez-Rodriguez et al. [85] showed a potential influence of the CCR5Δ32 deletion on the risk of CV disease among patients with RA. This may be due to a protective effect of this allelic variant against the development of vascular endothelial dysfunction.

The AD associated factors include a broad spectrum of autoantibodies as well as RA characteristics. The autoantibodies include RF [25, 49, 86], anti-CCP, aCL, anti-B2GPI, anti-HSP 60/65 [25, 30, 51, 55], and anti-oxLDL [30, 87, 88]. The RA characteristics are inflammatory basis [39, 89, 90], high disease activity [91], long duration [25], systemic involvement [56, 76, 92], treatment (systemic steroids) [93–95], and others, recently described, such as polyautoimmunity [25, 46, 55, 58] and familial autoimmunity [25].

Other issues, such as thrombogenic factors, which include vWF and fibrinogen levels, are related to CVD as well [49, 96, 97]. Several new cardiovascular risk factors in RA have received only modest attention and the different studies have shown contradictory results in LA patients. Each of these factors contribute to an impaired endothelial function, increased IMT, accelerated atherosclerosis, and finally, manifest CVD. For details, see Table 3.

4.4. Discovering Novel Nontraditional Risk Factors. Despite of all the traditional risk factors that have been associated with CVD in RA patients, the literature on it with respect to LA and the Caribbean is still scarce. Even though it has been generally accepted that systemic activity is related to chronic inflammation and accelerated pathogenic processes leading to cardiovascular compromise, it is important to assess other novel factors in patients that may also contribute. Therefore, we believe further research is needed in order to establish other factors that are not currently taken into account. To date, there are no systematic reviews of literature involving LA patients as a minority group.

After the systematic search was done, 2,119 RA patients from different LA countries were included and evaluated for cardiovascular outcomes in studies ranging from 1993 to 2012 (see Supplementary Table 1 in Supplementary Material available online at doi:1155/2012/371909). Common limiting factors in the sixteen studies analyzed included a lack of prospective follow up of RA patients and a general limitation on sample sizes. Most of the studies were either cross-sectional or case-control which in terms of evidence place them at level 4 [45]. Moreover, 50% of the studies included in the analysis had sample sizes of more than 100 RA patients. The rest of them had limited numbers of patients included, which was another common limit or bias found in the retrieved studies. Furthermore, the lack of adequate statistical methods and hypothesis testing in some of the studies should be noted. This was the case for four of the studies, which were descriptive or did not calculate P values, adjusted odds ratio or confidence intervals.

There is insufficient literature regarding CVD in LA patients with RA. Although the number of patients assessed is not negligible, when the geographical area of LA, the diversity, and the admixture of the population are considered, there is a need to include true cohorts to ensure more decisive conclusions.
### Table 3: Traditional and non-traditional risk factors associated with cardiovascular disease and rheumatoid arthritis in Latin America.

| Risk factor associated with CVD | Comments | Reference(s) |
|--------------------------------|----------|--------------|
| **Traditional**                |          |              |
| Hypertension                   | Increases the risk to suffer IHD or stroke with an important impact on mortality in patients with RA | [16] |
| T2DM                           | Patients with RA have a similar risk of developing CVD when compared to the same risk in patients with T2DM. Unfortunately, when there is a coexistence of both diseases, this risk is increased by three times | [69] |
| Dyslipidemia                   | Altered lipid profiles in RA patients are related with higher probability of IHD by accelerating atherosclerosis | [25, 70] |
| MetS                           | Is characterized for an alteration in production/secrection of proinflammatory adipokines and leads to increased activity of RA and accelerating atherosclerosis. Studies about the prevalence of MetS in LA patients have not achieved definitive conclusions, although its presence has been directly associated with a worse prognosis. In RA patients, was related with pain and functional status, suggesting disease activity. Therefore, a better control of disease activity may reduce CVD risk | [68, 71, 53, 50] |
| Hyperhomocysteinemia           | Homocysteine is considered as biomarker for atherosclerosis and a risk factor related with CAD and stroke. There is still controversy about whether hyperhomocysteinemia is a causative agent of cardiovascular damage or only an epiphenomenon of inflammation. A high prevalence of this biomarker in Mexican patients with RA had a statistical association with male gender and higher radiological damage. High homocysteine concentration can be an important risk marker for CVD in Chilean patients with RA, as it was significantly associated. | [22, 72, 48, 30] |
| **Nontraditional**             |          |              |
| Genetic                        |          |              |
| HLA-DRB1 SE alleles            | Related with chronic inflammation, endothelial dysfunction, and premature death for CVD. Associated with severe RA and with more EAM, high activity, and systemic inflammation. Being a carrier of a single copy of HLA-DRB1 SE were significantly associated with an increased risk of atherosclerotic plaque in RA Colombian patients. | [73–75, 74–77, 79, 25] |
| Polyautoimmunity               | Some articles included patients with poliautoimmunity, but no correlation with CVD subphenotypes was described | [25, 46, 55, 58] |
| Familial autoimmunity          | Was associated with presence of atherosclerotic plaque in RA Colombian patients. High titers have been established to be a predictor of CVD due to immune complex formation and tissue injury. It has been shown that such immune complexes from RF can be deposited in the endothelium and through inflammatory reactions generate endothelial disfunction and atherosclerotic process. | [25, 86] |
| RF positivity                  | RF seropositivity was significantly associated with an increased risk of endothelial dysfunction in RA Colombian patients. A statistical association between increased IMT, atherosclerosis plaque, and presence of RF was described in Mexican population with RA. Promote instability and rupture of the atheromatous plaque within the coronary arteries. | [24, 49, 88] |
| anti-oxLDL                     | Only one LA study evaluated this antibodies, but no correlation with CVD was found. The presence of plaques was higher in Brazilian patients with RA, but no correlation between IMT or plaques and autoantibodies were found. | [30, 51] |
| Other autoantibodies           | Other autoantibodies were assessed in LA population, such as aCL, anti-β2GPI, anti-HSP 60/6, and anti-CCP antibodies with no association regarding CVD outcomes. | [25, 30, 51, 55] |
| Inflammatory markers           | The association of inflammatory pathways with CVD is complex and is composed of several intermediate factors, including dyslipidemia, homocysteinemia, insulin resistance, and endothelial dysfunction. | [89] |
4.5. Assessing CVD in RA Patients. Heart disease in patients with RA is a major concern. Rheumatologists often face the question of how to treat and prevent CVD. To appropriately do so, we need to answer three important questions. (1) How do we estimate the risk of CVD in RA? Unfortunately, neither the Framingham Risk Score nor Reynolds’s Risk Score were designed to estimate risk in RA patients. The European League Against Rheumatism published their recommendation on estimating cardiovascular risk in RA; however, this has not been validated yet. (2) Which actions decrease CVD risk? Eating a well-balanced diet, exercising on a regular basis, quitting smoking, and maintaining a healthy weight have a positive impact on cardiovascular health. Targets based on the individual risk profile of every patient also have to be set. Well-established risk factors such as blood pressure, LDL levels, and hemoglobin A1C need to be considered. Treatments that reduce these risk factors include angiotensin-converting enzyme inhibitors, statins, and, in some patients, metformin. (3) What should be the target of all these efforts? That question raises more questions. Inflammation in RA is a risk factor for CVD which can be treated effectively, but can targeting “inflammation” decrease CVD risk in RA? Should the target be remission, a low CRP level, or lack of swollen joints? Is targeting specific inflammatory pathways more effective for reducing cardiovascular risk than other therapies? There are many unanswered questions and a lot of controversy about how to best address cardiovascular risk in patients with RA. Therefore, a comprehensive multidisciplinary approach is the first step towards addressing this complex issue and to optimize patient outcomes [98].

5. Conclusions

RA and CVD share common pathophysiology mechanisms (i.e., systemic and chronic inflammation) with secondary accelerated atherosclerosis that can explain the high mortality rates and augmented risk of ischemic events in these patients. Therefore, early or subclinical atherosclerosis should be assessed in every patient through the measurement of IMT in carotid arteries and other inflammatory markers on a regular clinical basis.

LA patients are ethnically different from other populations and have a worse disease course due to their different genetic burden that could be the cause of a higher prevalence of EAM. Trying to extrapolate previous results from countries with patients from a different ethnic group to our subpopulation could be a mistake.

Although there is an evident association of traditional risk factors and cardiovascular compromise in RA patients, they do not completely explain the high rates of CVD in these patients. Thus, novel risk factors which are related to autoimmunity are now becoming a more important focus.
of attention. This is the reason why we propose to separate traditional and nontraditional risk factors and evaluate them comprehensively and in a multidisciplinary fashion.

There is a lack of literature about CVD in Hispanic patients as demonstrated by this systematic search. To make matters worse, literature evaluating nontraditional risk factors is scarce. This should be a challenge to the rheumatologist to do research in these fields in order to elucidate the underlying mechanisms involved for the benefit of the patient.

Unfortunately, LA patients receive lower quality diagnostic assessment and treatment choices than Caucasian patients due to difficulties in access to health services and delayed diagnosis. Cardiovascular compromise in RA patients is a therapeutic challenge and doctors need to be committed to assessing, monitoring, and treating cardiovascular risk factors in the early stages as well as generating effective public health policies in developing LA countries so that morbidity rates can be decreased promptly.

### Abbreviations

- **CVD**: Cardiovascular disease
- **RA**: Rheumatoid arthritis
- **LA**: Latin America
- **EAM**: Extraarticular manifestations
- **T2DM**: Type 2 diabetes mellitus
- **MetS**: Metabolic syndrome
- **AD**: Autoimmune disease
- **IMT**: Intima-media thickness
- **CAD**: Coronary artery disease
- **MI**: Myocardial infarction
- **CHF**: Congestive heart disease
- **IHD**: Ischemic heart disease
- **VHL**: Virtual health library
- **SE**: Shared epitope
- **RF**: Rheumatoid factor
- **Anti CCP**: Anti-cyclic citrullinated peptide antibodies
- **aCL**: Anticardiolipin antibodies
- **Anti-B2GPI**: Anti-β2 glycoprotein I antibodies
- **Anti-oxLDL**: Antioxidized low-density lipoprotein antibodies
- **Anti-HSP 60/65**: Antinuclear heat shock proteins 60/65 antibodies
- **CRP**: C-Reactive Protein
- **ESR**: Erythrocyte sedimentation rate
- **DAS-28**: Disease activity score-28
- **SDAI**: Simplified disease activity index
- **MTX**: Methotrexate
- **vWF**: von Willebrand factor
- **WHO**: World Health Organization
- **MHAQ**: Modified Health Assessment Questionnaire
- **DMARDs**: Disease nodifying anti rheumatic drugs

### Conflict of Interests

The authors declare no conflict of interests.

### Acknowledgments

The authors are grateful to the all the members of Center for Autoimmune Diseases Research (CREA) for their fruitful discussions and contributions to this paper. This work was supported by the School of Medicine and Health Sciences of Universidad del Rosario in Bogotá, Colombia.

### References

1. D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” *The Lancet*, vol. 376, no. 9746, pp. 1094–1108, 2010.
2. A. N. DeMaria, “Relative risk of cardiovascular events in patients with rheumatoid arthritis,” *American Journal of Cardiology*, vol. 89, no. 6, pp. 33D–38D, 2002.
3. A. Sandoo, J. C. S. Veldhuijzen van Zanten, G. S. Metsois, D. Carroll, and G. D. Kitas, “Vascular function and morphology in rheumatoid arthritis: a systematic review,” *Rheumatology*, vol. 50, pp. 2125–2139, 2011.
4. P. Sarzi-Puttini, F. Atzeni, R. Gerli et al., “Cardiac involvement in systemic rheumatic diseases: an update,” *Autoimmunity Reviews*, vol. 9, no. 12, pp. 849–852, 2010.
5. A. Farzanbeh-Far and M. J. Roman, “Accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus,” *International Journal of Clinical Practice*, vol. 59, no. 7, pp. 823–824, 2005.
6. H. R. Kramer and J. T. Giles, “Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity,” *Arthritis Care & Research*, vol. 63, no. 4, pp. 484–499, 2011.
7. E. Myasoedova and S. E. Gabriel, “Cardiovascular disease in rheumatoid arthritis: a step forward,” *Current Opinion in Rheumatology*, vol. 22, no. 3, pp. 342–347, 2010.
8. N. Sattar and I. B. Mclnnes, “Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions,” *Current Opinion in Rheumatology*, vol. 17, no. 3, pp. 286–292, 2005.
9. S. M. A. Tolozo, A. G. Uribe, G. McGwin et al., “Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events,” *Arthritis and Rheumatism*, vol. 50, no. 12, pp. 3947–3957, 2004.
10. Y. Sherer and Y. Shoefeld, “Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis,” *Current Atherosclerosis Reports*, vol. 3, no. 4, pp. 328–333, 2001.
11. K. Veres, G. Lakos, A. Kerényi et al., “Antiphospholipid antibodies in acute coronary syndrome,” *Lupus*, vol. 13, no. 6, pp. 423–427, 2004.
12. R. Cervera, “Coronary and valvular syndromes and antiphospholipid antibodies,” *Thrombosis Research*, vol. 114, no. 5–6, pp. 501–507, 2004.
13. S. Guiducci, R. Giacomelli, and M. M. Cerinic, “Vascular complications of scleroderma,” *Autoimmunity Reviews*, vol. 6, no. 8, pp. 520–523, 2007.
14. M. Pérez-De-Lis, M. Akashi, A. Sisó et al., “Cardiovascular risk factors in primary Sjögren’s syndrome: a case-control study in 624 patients,” *Lupus*, vol. 19, no. 8, pp. 941–948, 2010.
15. A. Stavropoulos-Kalinoglou, G. S. Metsois, V. F. Panoulas et al., “Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 68, no. 2, pp. 242–245, 2009.
16. V. F. Panoulas, G. S. Metsois, A. V. Pace et al., “Hypertension in rheumatoid arthritis,” *Rheumatology*, vol. 47, no. 9, pp. 1286–1298, 2008.
patients without cardiovascular risk factors," Clinical Rheumatology, vol. 26, no. 4, pp. 533–537, 2007.

[50] A. Zoana-Nacach, E. Santana-Sahagún, F. J. Jiménez-Baldres, and A. Camargo-Coronel, "Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus," Journal of Clinical Rheumatology, vol. 14, no. 2, pp. 74–77, 2008.

[51] I. Pereira, L. Laurindo, R. Burlingame et al., "Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis," Joint Bone Spine, vol. 75, no. 4, pp. 416–421, 2008.

[52] I. A. Pereira, I. M. M. Laurindo, A. F. Zimmermann, G. R. W. Castro, F. Melo, and E. F. Borba, "Single measurements of C-reactive protein and disease activity scores are not predictors of carotid attherosclerosis in rheumatoid arthritis patients," Arq Bras Cardiol, vol. 84, no. 2, pp. 115–121, 2005.

[53] C. Turesson, W. M. Fallon, C. S. Crowson, S. E. Gabriel, and T. J. Christianson, "Prevalence of HLA-DRB1 alleles is associated with an increased risk of first ever cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis," Arthritis Care & Research, vol. 59, no. 6, pp. 673–681, 2007.

[54] C. Gonzalez-Juanatey, A. T este, A. Garcia-Castelo et al., "HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis," Arthritis Care & Research, vol. 59, no. 6, pp. 673–681, 2007.

[55] C. Gonzalez-Juanatey, A. T este, A. Garcia-Castelo et al., "HLA-DRB1 status and systemic lupus erythematosus disease activity: a meta-analysis of observational studies," Arthritis Care & Research, vol. 59, no. 12, pp. 1590–1597, 2008.

[56] J. Lindhardsen, O. Ahlehoff, G. H. Gislason, O. R. Madsen, J. B. Olesen, J. H. Svendsen et al., "Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study," British Medical Journal, vol. 344, article, 2012.

[57] C. Gonzalez-Juanatey, J. Llorca, J. Martin, and M. A. Gonzalez-Gay, "Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis," Arthritis Care & Research, vol. 66, no. 10, pp. 1451–1459, 2014.

[58] C. Gonzalez-Juanatey, J. Llorca, J. Martin, and M. A. Gonzalez-Gay, "Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis," Arthritis Care & Research, vol. 66, no. 10, pp. 1451–1459, 2014.
arthritis,” *Seminars in Arthritis and Rheumatism*, vol. 38, no. 5, pp. 366–371, 2009.

[81] V. F. Panoulas, K. M. J. Douglas, J. P. Smith et al., “Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis,” *Endothelium*, vol. 15, no. 4, pp. 203–212, 2008.

[82] R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis,” *Arthritis Research and Therapy*, vol. 12, no. 2, article R871, 2010.

[83] L. Rodríguez-Rodríguez, C. González-Juanatey, R. Palomino-Morales et al., “TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis,” *Atherosclerosis*, vol. 216, no. 1, pp. 125–130, 2011.

[84] R. López-Mejas, M. García-Bermúdez, C. González-Juanatey, S. Castañeda, J. A. Miranda-Filloy, C. Gómez-Vaquero et al., “NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis,” *Atherosclerosis*, vol. 224, no. 2, pp. 426–429, 2012.

[85] L. Rodríguez-Rodríguez, C. González-Juanatey, M. García-Bermúdez, T. R. Vázquez-Rodríguez, J. A. Miranda-Filloy, B. Fernández-Gutiérrez et al., “CCR5 Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study,” *Arthritis Research & Therapy*, vol. 13, article R133, 2011.

[86] M. Heliovaara, K. Aho, P. Knekt, A. Aromaa, J. Maatela, and A. Reunanen, “Rheumatoid factor, chronic arthritis and mortality,” *Annals of the Rheumatic Diseases*, vol. 54, no. 10, pp. 811–814, 1995.

[87] S. H. Kim, C. K. Lee, Y. L. Eun et al., “Serum oxidized low-density lipoproteins in rheumatoid arthritis,” *Rheumatology International*, vol. 24, no. 4, pp. 230–233, 2004.

[88] A. M. B. Medeiros, C. A. Von Mühlen, M. A. Gidlund, R. Bodanese, M. G. V. Gottlieb, and L. C. Bodanese, “Antibodies against oxLDL and acute coronary syndrome,” *Arquivos Brasileiros de Cardiologia*, vol. 95, no. 1, pp. 47–54, 2010.

[89] M. H. Snow and T. R. Mikuls, “Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention,” *Current Opinion in Rheumatology*, vol. 17, no. 3, pp. 234–241, 2005.

[90] F. Ingegnoli, F. Fantini, E. G. Favalli et al., “Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-α blockade,” *Journal of Autoimmunity*, vol. 31, no. 2, pp. 175–179, 2008.

[91] B. J. Radovits, D. A. Popa-Diaconu, C. Popa et al., “Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 68, no. 8, pp. 1271–1276, 2009.

[92] H. Maradit-Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman, and S. E. Gabriel, “Cardiovascular death in rheumatoid arthritis: a population-based study,” *Arthritis and Rheumatism*, vol. 52, no. 3, pp. 722–732, 2005.

[93] M. J. L. Peters, D. P. M. Symmons, D. McCoyre et al., “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis,” *Annals of the Rheumatic Diseases*, vol. 69, no. 2, pp. 325–331, 2010.

[94] V. F. Panoulas, K. M. J. Douglas, A. Stavropoulos-Kalinoglou et al., “Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis,” *Rheumatology*, vol. 47, no. 1, pp. 72–75, 2008.